<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144438">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01676285</url>
  </required_header>
  <id_info>
    <org_study_id>0010/11</org_study_id>
    <nct_id>NCT01676285</nct_id>
  </id_info>
  <brief_title>Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis</brief_title>
  <acronym>CARE Cirrhosis</acronym>
  <official_title>Effect of Metoprolol Succinate in Cardiac Remodeling Related to Nonalcoholic Cirrhosis. Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <authority>Brazil: National Commission of Ethic in Researches - CONEP</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cirrhotic cardiomyopathy is defined as a chronic cardiac dysfunction in patients with
      cirrhosis. It is suspected that this specific cardiac dysfunction contributes to the onset
      of complications in liver disease. The purpose of this prospective, randomized trial is to
      determine whether metoprolol succinate can revert cardiac dysfunction secondary to cirrhosis
      (cirrhotic cardiomyopathy), and prevent complications (renal dysfunction, mortality). A
      total of 100 patients with cirrhotic cardiomyopathy will be randomized (Group R) to receive
      metoprolol succinate or placebo; other 25 patients without cirrhotic cardiomyopathy (Group
      F) will only be followed up without medication. All patients will be evaluated in the
      beginning and again after six months. The assessment protocol includes clinical evaluation,
      electrocardiogram, echocardiogram, laboratory analysis and life quality questionaire. The
      end points will be cardiac remodeling, electrophysiologic changes, sympathetic activity,
      laboratory issue changes, renal function, quality of life, and mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cirrhotic cardiomyopathy (CMC) is defined as a chronic cardiac dysfunction in patients with
      cirrhosis. Moreover, it is characterized by an abnormal and blunted response to pathological
      or pharmacological stress in the absence of any other associated cardiac disease. The
      diagnostic criteria are: baseline increased cardiac output, attenuated myocardial
      contractile response to stress, diastolic dysfunction, and electrophysiological
      repolarization abnormalities. It is suspected that cardiac dysfunction in cirrhosis
      contribute to the onset of complications in liver disease. We will investigate the effect of
      metoprolol succinate in the reversal of cardiac dysfunction and prevention of complications
      of cirrhosis in patients with cirrhotic cardiomyopathy. Furthermore, we want to study the
      influence of presence of CMC in the evolution of cirrhotic patients. The study will be
      prospective, randomized, double-blind, and placebo-controlled. The sample consists of 125
      patients aged between 18 and 60 years old diagnosed with severe liver cirrhosis (Child B or
      C or MELD score above 10) with cirrhotic cardiomyopathy or not. Of these, 100 patients with
      cirrhotic cardiomyopathy will be randomized into two groups: group R1 (metoprolol succinate)
      and group R2 (placebo). Group F will consist of cirrhotic patients without cardiomyopathy
      and will not receive medication. Patients will be evaluated by clinical examination, resting
      electrocardiogram, 24-hour Holter, stress echocardiography and laboratory (brain natriuretic
      peptide (BNP), catecholamines, plasma renin activity, and troponin) at inclusion and after
      six months. The end points are: 1) Reversal of cardiac dysfunction in patients with
      cirrhotic cardiomyopathy, 2) Development of hepatorenal syndrome, 3) Reversal of the
      electrophysiologic abnormalities, 4)Changes in laboratory tests, and 5) Mortality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement of systolic function</measure>
    <time_frame>six months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Systolic functional reserve is measured by aortic velocity time integral in echocardiographic at rest and stress with dobutamine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in left ventricular diastolic function</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>From randomization until six months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum level of BNP, catecholamines, plasmatic renin activity</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From randomization until six months of follow up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrophysiologic modifications</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>QT prolongation R-R variability</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Cirrhotic Cardiomyopathy</condition>
  <condition>Cardiac Remodeling</condition>
  <arm_group>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol succinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Follow up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group without cirrhotic cardiomyopathy, only follow up without randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol succinate</intervention_name>
    <arm_group_label>Metoprolol succinate</arm_group_label>
    <other_name>Selozok</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more than 18 years old.

          -  must have signed the written informed consent.

          -  nonalcoholic cirrhosis.

        Exclusion Criteria:

          -  Betablockers intolerance;

          -  Diagnosis of other cardiomyopathy

          -  Chronicle renal disease (Creatinine &gt; 2.5)

          -  Heavy alcohol intake history

          -  Presence of other disease with possible cardiac implication (infiltrative or storage
             disease)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Bacal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando Bacal, MD, PhD</last_name>
    <phone>+551126613338</phone>
    <email>fbacal@uol.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Odilson M Silvestre, MD</last_name>
    <phone>+551126613338</phone>
    <email>odilsonsilvestre@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Sao Paulo School of Medicine</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Bacal, MD, PhD</last_name>
      <phone>+551126613338</phone>
      <email>fbacal@uol.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Odilson M Silvestre, MD</last_name>
      <phone>+551126617830</phone>
      <email>odilsonsilvestre@yahoo.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Fernando Bacal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Odilson M Silvestre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Q Farias, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Flair J Carrilho, DM, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luiz AC D'Albuquerque, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José L Andrade</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meive Furtado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel F Mazo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 29, 2012</lastchanged_date>
  <firstreceived_date>August 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Fernando Bacal</investigator_full_name>
    <investigator_title>MD; PhD</investigator_title>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>cirrhotic cardiomyopathy</keyword>
  <keyword>cardiac remodeling</keyword>
  <keyword>cardiomyopathy</keyword>
  <keyword>metoprolol succinate</keyword>
  <keyword>betablockers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Metoprolol succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
